BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35477451)

  • 1. The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy.
    Jiang H; Dong Y; Zong W; Zhang XJ; Xu H; Jin F
    BMC Womens Health; 2022 Apr; 22(1):135. PubMed ID: 35477451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
    Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
    Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing Symptom Distress: Key Factors for Patients on Adjuvant Endocrine Therapy for Breast Cancer.
    Post KE; Ahmad Z; Jankauskaite G; Centracchio J; Oswald L; Horick N; Park ER; Temel JS; Greer JA; Jacobs J
    J Pain Symptom Manage; 2024 Jan; 67(1):88-97. PubMed ID: 37816436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
    Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
    Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
    Sheppard VB; Dash C; Nomura S; Sutton AL; Franco RL; Lucas A; Ross M; Adams-Campbell L
    Cancer; 2020 Sep; 126(17):4059-4066. PubMed ID: 32614992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer.
    Paladino AJ; Anderson JN; Krukowski RA; Waters T; Kocak M; Graff C; Blue R; Jones TN; Buzaglo J; Vidal G; Schwartzberg L; Graetz I
    BMC Health Serv Res; 2019 Dec; 19(1):977. PubMed ID: 31856812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between medication adherence and illness perception in breast cancer patients with adjuvant endocrine therapy: beliefs about medicines as mediators.
    Zhao M; Zhao J; Chen J; Li M; Zhang L; Luo X; Zhang Y; Xiong C; Guo Z; Yan J
    Support Care Cancer; 2022 Dec; 30(12):10009-10017. PubMed ID: 36261611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
    Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
    Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
    Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
    Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy.
    Akin Telli T; Ozturk MA; Alan O; Hasanov R; Kostek O; Arikan R; Basoglu T; Kaya S; Ercelep O; Akgul Babacan N; Dane F; Yumuk PF
    Future Oncol; 2022 Jul; 18(22):2425-2439. PubMed ID: 35695547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of the HT&Me intervention to support women with breast cancer to adhere to adjuvant endocrine therapy and improve quality of life.
    Stewart SF; Slodkowska-Barabasz J; McGeagh L; Moon Z; Brett J; Wells M; Brown MC; Turner M; Horne R; Fenlon D; Rehman F; Cain H; Donnelly P; Harmer V; Turner L; Rose J; Sharp L; Watson E;
    Breast; 2023 Aug; 70():32-40. PubMed ID: 37300986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer.
    Lee JY; Min YH
    BMC Womens Health; 2018 Mar; 18(1):48. PubMed ID: 29551094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent factors associated with adherence to adjuvant endocrine therapy among women with non-metastatic breast cancer.
    Walsh EA; Walsh LE; Hernand M; Horick N; Antoni MH; Temel JS; Greer JA; Jacobs JM
    J Cancer Surviv; 2024 Feb; ():. PubMed ID: 38401012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
    Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The experiences of adjuvant endocrine therapy for women breast cancer survivors: A literature review.
    Long Y; Xie S; Liu Q; Xu F; Li Q; Wang N; Zhang Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36704. PubMed ID: 38134074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
    Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
    Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors.
    Bright EE; Finkelstein LB; Nealis MS; Genung SR; Wrigley J; Gu HCJ; Schmiege SJ; Arch JJ
    J Clin Oncol; 2023 Oct; 41(28):4548-4561. PubMed ID: 37531593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
    Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
    Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
    JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.